<DOC>
	<DOCNO>NCT01272414</DOCNO>
	<brief_summary>Currently therapeutic option treatment lid retraction secondary thyroid orbitopathy ( TO ) active stage disease . BoTox injection capable create ptosis , set TO return upper lid physiologic position , thus improve cosmesis , corneal lubrication potentially quiescent stage lid position . This investigation aim examine property relationship .</brief_summary>
	<brief_title>Use Botox Management Thyroid Related Upper Eyelid Retraction</brief_title>
	<detailed_description />
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Graves Ophthalmopathy</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Active stage thyroid orbitopathy , determine symptom onset 6 month . Upper eyelid retraction 1mm great . Complaining either significant ocular symptom ( despite appropriate use ocular lubricant ) , bother cosmetic deformity associate eyelid retraction . Less 18 year age Age 65 year Pregnant nursing Known peripheral neuropathy neuromuscular junction disorder Demonstrated allergy BoTox Current infection injection site Are currently take follow medication : aminoglycosides , penicillamine , quinine , calcium channel blocker . Previous concurrent prednisone therapy Undergone previous upper eyelid surgery Severe vision threaten TO</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Eyelid retraction</keyword>
	<keyword>Botulinum Toxins</keyword>
</DOC>